Alpha Cancer Technologies

About Alpha Cancer Technologies

Alpha Cancer Technologies operates in the biotechnology sector, focusing on the development of targeted immuno-oncology therapies. The company specializes in creating advanced therapeutic platforms designed to treat various forms of cancer by leveraging the body's immune system. Their core products include the ACT 900 Series and ACT 101, which are aimed at enhancing the efficacy of cancer treatments. Alpha Cancer Technologies primarily serves pharmaceutical companies and healthcare providers looking for cutting-edge cancer treatment solutions. The company generates revenue through partnerships, licensing agreements, and equity investments, such as the notable $10.5 million investment from Celgene, which holds a 15% equity stake. The market for immuno-oncology is rapidly growing, driven by the increasing prevalence of cancer and the need for more effective treatments. Alpha Cancer Technologies positions itself as a key player in this market by offering innovative solutions that promise to improve patient outcomes and advance cancer treatment methodologies.